KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Net Cash Flow (2016 - 2025)

Edwards Lifesciences has reported Net Cash Flow over the past 17 years, most recently at $241.2 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $241.2 million for Q4 2025, up 135.7% from a year ago — trailing twelve months through Dec 2025 was -$74.5 million (down 103.98% YoY), and the annual figure for FY2025 was -$74.5 million, down 103.98%.
  • Net Cash Flow for Q4 2025 was $241.2 million at Edwards Lifesciences, up from -$594.2 million in the prior quarter.
  • Over the last five years, Net Cash Flow for EW hit a ceiling of $2.1 billion in Q3 2024 and a floor of -$675.6 million in Q4 2024.
  • Median Net Cash Flow over the past 5 years was $122.8 million (2021), compared with a mean of $84.8 million.
  • Biggest five-year swings in Net Cash Flow: plummeted 460.89% in 2021 and later surged 827.79% in 2023.
  • Edwards Lifesciences' Net Cash Flow stood at -$654.3 million in 2021, then grew by 29.56% to -$460.9 million in 2022, then surged by 43.05% to -$262.5 million in 2023, then crashed by 157.37% to -$675.6 million in 2024, then soared by 135.7% to $241.2 million in 2025.
  • The last three reported values for Net Cash Flow were $241.2 million (Q4 2025), -$594.2 million (Q3 2025), and $170.8 million (Q2 2025) per Business Quant data.